2019 Winners
We’re excited to celebrate the four changemakers helping to make a difference in the lives of people affected by cancer. Learn more about their stories.
C2 Catalyst for Care Award
The Centers of Excellence program of the GO2 Foundation for Lung Cancer
Represented by Leah Fine, Senior Director
Most patients seek care close to home – but home can be a long way from a leading cancer center. The Centers of Excellence program of the GO2 Foundation for Lung Cancer is taking on geographic inequality by helping community hospitals develop world-class care.
C2 Catalyst for Precision Medicine Award
Barbara Gitlitz, MD and Geoffrey Oxnard, MD
Co-Principal Investigators, The Genomics of Young Lung Cancer Study
Drs. Barbara Gitlitz and Geoffrey Oxnard found that 80% of young lung cancer patients under 40 shared a genetic mutation that was targetable with known treatments.
President’s Award
Ovarian Cancer Research Alliance’s Survivors Teaching Students®
Represented by Susan Leighton, National Program Director Audra Moran, President & CEO
To improve the early diagnosis of ovarian cancer, Survivors Teaching Students® uses ovarian cancer survivors to educate medical students about the disease’s warning signs – before it’s too late.
2019 Finalists
Congratulations to the finalists who have been recognized by their peers for the inspiring work they do each day – all to create a brighter future for those living with and affected by cancer.
C2 Catalyst for Change Award
Finalists for this award bring high-quality cancer care to underserved populations. Consequently, their work drives change at the community-, neighborhood or hospital-level that results in better cancer care for more people.
C2 Catalyst for Care Award
This group of finalists improves the cancer-care experience for people with cancer and their loved ones. As a result, the work of these finalists makes a patient’s experience as easy as possible during an extraordinarily difficult time.
C2 Catalyst for Precision Medicine Award
A finalist for this award significantly advances precision medicine in oncology to bring new, more personalized tests or treatments to patients. As such, these finalists enhance the ability to provide the right treatment for the right patient at the right time.